Colorectal carcinoma (CRC) · line 2 · Pembrolizumab monotherapy (MSI-H mCRC 1L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-PEMBROLIZUMAB-MSI-MONO |
| ID | IND-CRC-METASTATIC-2L-MSI-H-PEMBRO |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-CRC |
| Sources | SRC-ESMO-COLON-2024 SRC-KEYNOTE-164-LE-2020 SRC-KEYNOTE-177-ANDRE-2020 SRC-NCCN-COLON-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L+ for MSI-H/dMMR mCRC missed at 1L OR where pembrolizumab was unavailable in 1L. Trial-specific source (KEYNOTE-164 PMID 33264544) not in KB yet — flagged for CSD-4.5. Pembrolizumab access remains dominant rate-limiter in Ukraine.
Used By
Algorithms
ALGO-CRC-METASTATIC-2L- ALGO-CRC-METASTATIC-2L